Takeover

Sodexo and the Humane Society of the United States Team up to Tackle Climate Change with Plant-based Meals

Retrieved on: 
星期二, 四月 19, 2022
Innova, Water, Health, Government, Carbon, Climate change, Faculty, Fortune 500, Twitter, Student, Hunger, HSUS, YouTube, GLOBE, Education, Program, LinkedIn, RDN, Humanity (virtue), Volunteering, Animal, Humane society, Takeover, Instagram, Safety, Industry, Quality of life, Brothers in Unity, University, Renewable energy, Agriculture, Restaurant, Sodexo, Facebook

The new initiatives focus on increasing plant-based menu options that will end up on Sodexo menus at hundreds of universities across the United States.

Key Points: 
  • The new initiatives focus on increasing plant-based menu options that will end up on Sodexo menus at hundreds of universities across the United States.
  • Overall, Sodexo is committed to serving plant-based meals wherever and whenever possible in an effort to reduce the impacts of climate change.
  • Founded in 1954, the Humane Society of the United States fights the big fights to end suffering for all animals.
  • We fight all forms of animal cruelty to achieve the vision behind our name: A humane society.

Quidel Announces Preliminary Revenue for First Quarter 2022

Retrieved on: 
星期四, 四月 7, 2022
Biotechnology, General Health, Medical Devices, Infectious Diseases, Health, Private Securities Litigation Reform Act, City Code on Takeovers and Mergers, England, Youth justice in England and Wales, Linear code, NASDAQ, Form, Dangerous, Growth, Attention, Patient, Compliance, Takeover, Ownership, High Court, Commission, Corporation, Reading, Telephone, Failure, Food, U.S. Securities and Exchange Commission, Government, JOINT, Security (finance), THE, TO, Form S-4, Nasdaq, COVID-19, Tax, Regulation of tobacco by the U.S. Food and Drug Administration, Physician, Information technology, Mergers and acquisitions, Nature, Ortho, FDA, Terminology, SVC, Acquisition, Emergency Use Authorization, Infection, Pharmaceutical industry, Risk management, Quidel Corporation

COVID-19 product revenues in the first quarter of 2022 are expected to be approximately $836 million, composed of approximately $657 million in QuickVue COVID-19 test revenue and approximately $138 million in Sofia SARS antigen test revenue.

Key Points: 
  • COVID-19 product revenues in the first quarter of 2022 are expected to be approximately $836 million, composed of approximately $657 million in QuickVue COVID-19 test revenue and approximately $138 million in Sofia SARS antigen test revenue.
  • We had another outstanding quarter and an excellent start to the year, delivering a record quarter for revenue, said Douglas Bryant, President and Chief Executive Officer of Quidel.
  • These preliminary results are based on managements initial analysis of operations for the quarter ended March 31, 2022.
  • Quidel expects to issue full financial results for the first quarter of 2022 in May.

Statement Regarding Possible Offer for Clipper Logistics plc

Retrieved on: 
星期日, 二月 20, 2022
Depreciation, Risk, Financial adviser, Open position, Exchange, Compliance, Calendar, International Securities Identification Number, Financial Conduct Authority, EBIT, GXO, Uncertainty, COVID-19, Industry, London Stock Exchange, United Kingdom, IFRS, Sale, Nature, City Code on Takeovers and Mergers, Documentation, Person, Par value, Possibility, Pandemic, Securities Act of 1933, Disclosure, Forward-looking statement, Rothschild & Co, Takeover, Lists of disasters, Clipper, EBITDA, London, Silviculture, Security (finance), Health insurance, Holding company, Bloomberg, Numis

GREENWICH, Conn., and LONDON, Feb. 20, 2022 (GLOBE NEWSWIRE) -- The Boards of Clipper Logistics plc (“Clipper”) and GXO Logistics, Inc. (“GXO”) are pleased to announce that they have reached agreement on the key terms of a possible cash and share offer for Clipper by GXO (the “Possible Offer”).

Key Points: 
  • Any offer, if made, will be made solely by certain offer documentation which will contain the full terms and conditions of any offer, including details of how it may be accepted.
  • If GXO ultimately seeks to implement the transaction by way of a takeover offer, that offer will be made in compliance with applicable US laws and regulations.
  • The forward-looking statements contained in this document include statements relating to the expected effects of the Offer on Clipper and/or GXO, the expected timing and scope of the Offer, and other statements other than historical facts.
  • The following Clipper shareholders have given irrevocable undertakings to GXO to (i) vote in favour of the Possible Offer at any court meeting (or, in the event that the Possible Offer is implemented by way of a takeover offer rather than a scheme of arrangement, accept the takeover offer); and (ii) elect to receive 50 per cent.

NortonLifeLock Delivers Double-Digit Growth in Q3 Fiscal 2022

Retrieved on: 
星期四, 二月 3, 2022
Growth, Takeover, Legislation, Audit committee, NLOK, Terrorism, Elementary cellular automaton, Goal, Form, Efficiency, COVID-19, Risk, Safety, Acquisition, U.S. Securities and Exchange Commission, Review, GAAP, The High End of Low, City Code on Takeovers and Mergers, CEO, Economic policy of the Joe Biden administration, Mission statement, Company, Income, NASDAQ, Earnings, Cyber Safety Review Board, Finance, Forecasting, Investor relations, Method, IR, Linear code, NXT UK TakeOver: Cardiff, Industry, EPS, Panel, Behavior, CFO, Lists of disasters, Board, High-end audio, Panel on Takeovers and Mergers, Bank, Management, Bookkeeping, Cryptocurrency, Silviculture, Retail, Holding company, Property management, Marketing, Risk management, Mergers and acquisitions, USD, Avast, NortonLifeLock

TEMPE, Ariz., Feb. 3, 2022 /PRNewswire/ -- NortonLifeLock Inc. (NASDAQ: NLOK), a global leader in consumer Cyber Safety, today released results for its fiscal year 2022 third quarter which ended December 31, 2021.

Key Points: 
  • TEMPE, Ariz., Feb. 3, 2022 /PRNewswire/ -- NortonLifeLock Inc. (NASDAQ: NLOK), a global leader in consumer Cyber Safety, today released results for its fiscal year 2022 third quarter which ended December 31, 2021.
  • "We delivered double-digit revenue and bookings growth, and nine consecutive quarters of sequential customer growth," said Natalie Derse, CFO of NortonLifeLock.
  • However, the NortonLifeLock Profit Forecast assumes that completion has not occurred by April 1, 2022 in order for NortonLifeLock shareholders to assess the performance of NortonLifeLock on a standalone basis.
  • For the purposes of Rule 28 of the UK Takeover Code, the NortonLifeLock Profit Forecast contained in this press release is the responsibility of NortonLifeLock and the NortonLifeLock Directors.

EQS-News: IMMOFINANZ: CPI offer price too low

Retrieved on: 
星期四, 一月 27, 2022
Zero, Comparable, Supervisory board, Growth, Federal Executive Boards, Board of directors, TOP, Forward-looking statement, Climate change, Review, COVID-19, EPRA, Union, CPI Property Group, EUR, STOP, IFRS, Greenhouse, VIVO, CPI, ATX, Takeover, Intention, Economic development, Works council, Supervision, Reference, Acquisition, Security (finance), Renewable energy, Risk management, Adriatic Sea, Central Europe

The offer price does not include any premium to the uninfluenced closing price on 2 December 2021, the day before the announcement of the intention to make a takeover offer.

Key Points: 
  • The offer price does not include any premium to the uninfluenced closing price on 2 December 2021, the day before the announcement of the intention to make a takeover offer.
  • Additionally, the offer price is 6.4% below the current price of the IMMOFINANZ share on 24 January 2022.
  • The offer price is also significantly below the price of the IMMOFINANZ share before the outbreak of the COVID-19 pandemic (nearly EUR 27 in February 2020) and the analysts' average target price of EUR 24.50 (median).
  • The conditions and further provisions relating to the Takeover Offer are disclosed in the offer document published by CPI PROPERTY GROUP S.A.

Ortho Clinical Diagnostics Holdings Plc (“Ortho”): Notice of UK Court Scheme Directions Hearing

Retrieved on: 
星期一, 一月 24, 2022
Private Securities Litigation Reform Act, Youth justice in England and Wales, Attention, Companies Act 2006, U.S. Securities and Exchange Commission, Commission, SVC, Nature, Computershare, Depository Trust & Clearing Corporation, JOINT, Company, Microsoft, Failure, Telephone, TO, Intention, Practice, Proxy, Takeover, Part, Ownership, Mergers and acquisitions, Software, Trust, IR, Securities Act of 1933, Topco, THE, Hearing, England, High Court, GLOBE, Form, Sale, Communication, Security (finance), Prospectus, Terminology, Online gambling, Cryptocurrency, Risk management, Ortho, Quidel Corporation

The UK Scheme Directions Hearing is expected to take place on February 15, 2022.

Key Points: 
  • The UK Scheme Directions Hearing is expected to take place on February 15, 2022.
  • It is a matter for the UK Court as to whether the hearing is in person, virtual only using Microsoft Teams (or such other videoconferencing software as the UK Court decides) or hybrid.
  • The documents filed with the UK Court in connection with the UK Scheme Directions Hearing will be made available on Orthos website at https://ir.orthoclinicaldiagnostics.com as soon as practicable after each document is filed at the UK Court in connection with the UK Scheme Directions Hearing.
  • If any shareholders have any questions relating to UK Scheme Directions Hearing they are encouraged to make contact by emailing [email protected].

EQS-News: IMMOFINANZ: S IMMO offer price too low

Retrieved on: 
星期一, 一月 10, 2022
Zero, Supervisory board, Federal Executive Boards, EPRA, Supervision, Growth, Takeover, EUR, STOP, Investment, Financial Oversight and Management Board for Puerto Rico, TOP, FFO, Forward-looking statement, IFRS, Review, Climate, Union, Greenhouse, COVID-19, Reference, ATX, VIVO, Board of directors, Climate change, Works council, Security (finance), Bank, Renewable energy, Adriatic Sea

The Executive Board and Supervisory Board therefore recommend that shareholders not accept the partial offer by S IMMO for approximately 10% of the outstanding IMMOFINANZ shares.

Key Points: 
  • The Executive Board and Supervisory Board therefore recommend that shareholders not accept the partial offer by S IMMO for approximately 10% of the outstanding IMMOFINANZ shares.
  • For example: The offer price is substantially lower than the current EPRA NTA per share of EUR 30.77 and represents a discount of roughly 25%.
  • Moreover, the S IMMO offer price does not reflect IMMOFINANZ's outstanding performance in 2021 or the potential of its value-creating strategy.
  • Consequently, we recommend that our shareholders not accept the offer from S IMMO because the specified price does not reflect the value of the company.

Quidel Announces Preliminary Revenue for Fourth Quarter 2021

Retrieved on: 
星期四, 一月 6, 2022
Other Manufacturing, Research, Technology, Medical Devices, Infectious Diseases, Manufacturing, General Health, Health, Data Management, Science, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Topco, Information technology, Security (finance), History, NASDAQ, FDA, Investor relations, Mergers and acquisitions, City Code on Takeovers and Mergers, Corporation, Commission, Form, Webcast, Physician, Attention, Private Securities Litigation Reform Act, High Court, Compliance, Youth justice in England and Wales, Linear code, Nasdaq, Professional, Dangerous, Nature, Food, Prospectus, Company, Ownership, Patient, Conference, Transfusion medicine, Sale, Terminology, Securities Act of 1933, Acceleration, U.S. Securities and Exchange Commission, Public health, Tax, JOINT, Takeover, TO, Acquisition, Government, Failure, THE, Telephone, Delta, England, SVC, Emergency Use Authorization, Pharmaceutical industry, Cryptocurrency, Risk management, Quidel Corporation, Omicron, Ortho

The fourth quarter of 2021 put the final exclamation point on a truly outstanding and transformational year for Quidel, said Douglas Bryant, President and Chief Executive Officer of Quidel.

Key Points: 
  • The fourth quarter of 2021 put the final exclamation point on a truly outstanding and transformational year for Quidel, said Douglas Bryant, President and Chief Executive Officer of Quidel.
  • In the fourth quarter of 2021, we sold approximately 65 million QuickVue COVID-19 antigen tests and over 4 million Sofia SARS antigen tests the highest quarterly sales volume for tests for Quidel.
  • These preliminary results are based on managements initial analysis of operations for the quarter ended December 31, 2021.
  • Quidel expects to issue full financial results for the fourth quarter of 2021 and full year 2021 in February.

SS&C Announces A Recommended Cash Offer For Blue Prism Group plc

Retrieved on: 
星期三, 十二月 1, 2021
Public expenditure, Government, Table, CEO, Blue Prism, Linear code, Takeover, Technology, Industry, SS&C Technologies, LAWS, RPA, SS&C, INTO, Proxy, Solution, Nature, SS, Vista, Prospectus, Policy, Software, View, Nasdaq, Public policy, Person, Growth, Multimedia, Failure, THE, Vista Equity Partners, Management, Security (finance), Health insurance, Risk management

Blue Prism is a leading robotics process automation (RPA) company headquartered in the UK, whose services are used by more than 2,000 businesses worldwide.

Key Points: 
  • Blue Prism is a leading robotics process automation (RPA) company headquartered in the UK, whose services are used by more than 2,000 businesses worldwide.
  • With SS&C's management focus, global salesforce, talented development organization, and significant capital resources, Blue Prism can reach new heights with its intelligent digital workforce.
  • SS&C's cash offer is higher than the current offer for Blue Prism by certain funds managed or controlled by Vista Equity Partners (the "Vista Offer").
  • Accordingly, the directors of Blue Prism intend to recommend unanimously that Blue Prism shareholders approve the Acquisition and have therefore decided to withdraw their recommendation of the Vista Offer.

DGAP-News: EQT AB: Acceptance period for Zorro Bidco's public delisting tender offer for all outstanding zooplus shares commences

Retrieved on: 
星期三, 十一月 24, 2021
Frankfurt Stock Exchange, Review, Financial Oversight and Management Board for Puerto Rico, German Federation of Consumer Organisations v Planet49 GmbH, Partnership, Takeover, Health, Physikalisch-Technische Bundesanstalt, Delisting, Software Technology Parks of India, Federal Financial Supervisory Authority, XETRA, Hellman & Friedman, EUR, CET, Börse Berlin, Investment, Orientation, Supervisory board, ISIN, BNP Paribas, AG, Tradegate Exchange, Growth, Philosophy, Frankfurt, EQT, Security (finance), Financial adviser, Hellman & Friedman, EQT, HELLMAN & FRIEDMAN, EQT

zooplus shareholders can tender their zooplus shares into the Delisting Offer at a price of EUR 480 per share in the Delisting Offer tender period which starts today and ends at midnight (CET) on 12 January 2022.

Key Points: 
  • zooplus shareholders can tender their zooplus shares into the Delisting Offer at a price of EUR 480 per share in the Delisting Offer tender period which starts today and ends at midnight (CET) on 12 January 2022.
  • This consideration corresponds to the offer price of the preceding voluntary public takeover offer by Zorro Bidco (the "Takeover Offer"), which ended on 22 November 2021.
  • At the end of the additional acceptance period of the Takeover Offer on 22 November 2021, more than 89 percent of zooplus' total shares have been tendered into the Takeover Offer.
  • The relevant details as to how the Delisting Offer can be accepted are set out in the offer document for the Delisting Offer.